CLAIMS

1. A compound of formula (I)



R represents halogen, $C_{1-4}$ alkyl, cyano, $C_{1-4}$ alkoxy, trifluoromethyl or trifluoromethoxy;
$R_1$ represents hydrogen, halogen, $C_{3-7}$cycloalkyl, hydroxy, nitro, cyano or $C_{1-4}$ alkyl optionally substituted by halogen, cyano or $C_{1-4}$ alkoxy;
$R_2$ represents hydrogen or $C_{1-4}$ alkyl;
$R_3$ and $R_4$ independently represent hydrogen, cyano, $C_{1-4}$ alkyl or $R_3$ together with $R_4$ represents $C_{3-7}$ cycloalkyl;
$R_5$ represents trifluoromethyl, $S(O)_t$ C $_{1-4}$ alkyl, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, trifluoromethoxy, halogen or cyano;
$R_6$ represents hydrogen or $(CH_2)rR_7$;
$R_7$ represents hydrogen, $C_{3-7}$ cycloalkyl, $NH(C_{1-4}alkylOC_{1-4}alkoxy)$, $NH(C_{1-4}alkyl)$, $N(C_{1-4}alkyl)_2$ , $OC(O)NR_9R_8$ , $NR_8C(O)5R_9$ or $C(O)NR_9R_8$;
$R_9$ and $R_8$ independently represent hydrogen, $C_{1-4}$ alkyl or $C_{3-7}$ cycloalkyl;
m represents zero or an integer from 1 to 4;
n represents 1 or 2;
p is zero or an integer from 1 to 3;
q is an integer from 1 to 3;
r is an integer from 1 to 4;
t is 0 , 1 or 2 ;
provided that when m is 0, p is 2, q , r and n represent 1, $R_1$, $R_2$,$R_3$, $R_4$, $R_5$ and $R_7$ are hydrogen and R is chlorine, $R_5$ is not iodine;
and pharmaceutically acceptable salts and solvates thereof.

2 A compound as claimed in claim 1 wherein R is halogen (e.g. fluorine or chlorine), cyano, trifluoromethyl or a $C_{1-4}$ alkyl (e.g. methyl) group and p is 0 or an integer from 1 to 2.

3. A compound as claimed in claims 1 or 2 wherein $R_5$ is trifluoromethyl, cyano, methyl or halogen and q is an integer from 1 to 2.

4. A compound as claimed in any claims 1 to 3 wherein $R_6$ is hydrogen or $(CH_2)_rR_7$ in which r is 1 or 2 and $R_7$ is hydrogen, cyclopropyl, $C(O)N(C_{1-4}\text{ alkyl})_2$, $C(O)NH(C_{1-4}\text{ alkyl})$ or $C_{1-4}$ alkoxy.

5. A compound as claimed in any claims 1 to 4 wherein R is $C_{1-4}$ alkyl, halogen (i.e chlorine or fluorine), trifluoromethyl or cyano; $R_1$ is hydrogen, methyl, ethyl or halogen (e.g. fluorine), $R_2$ is a methyl or hydrogen, $R_3$ and $R_4$ are independently hydrogen or methyl, $R_5$ is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine, $R_6$ hydrogen, methyl, ethyl methylcyclopropyl $(CH_2)_2OCH_3$ or $CH_2C(O)N(CH_3)_2$, p is 0 or an integer from 1 to 2, m is 0 or 1, n is 1 or 2, q is 1 or 2.

6. A compound as claimed in any claims 1 to 5 wherein m is 1.

7. A compound selected from:
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide ;
4-(4-Fluorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
4-(4-Chlorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
4-(4-Fluorophenyl)-piperidine-4-carboxylic acid (3,5-dichloro-benzyl)-methylamide;
N-(3,5-Bis-trifluoromethyl)-benzyl-2-[(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluorophenyl)-azepin-4-yl]-N-methyl-acetamide;
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;
N-(3,5-Dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-(3,5-Dibromobenzyl)-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;
N-(3,5-Dibromo-benzyl)-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;
N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;
N-[1-(3,5- Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
*N*-[(3,5-Dichlorophenyl)methyl]-2-{4-(4-fluoro-2-methylphenyl)-1-[2-(methyloxy)ethyl]-4-piperidinyl}-*N*-methylacetamide;
*N*-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]acetamide;
*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]acetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-(2-methylphenyl)-4-piperidinyl]acetamide;
*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-(2-methylphenyl)-4-piperidinyl]acetamide;
*N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide ;
N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
2-[1-(Cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;
2-[4-{2-[[(3,5-Dibromophenyl)methyl](methyl)amino]-2-oxoethyl}-4-(4-fluorophenyl)-1-piperidinyl]-*N*,*N*-dimethylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[1-ethyl-4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
*N*-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
*N*-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;
*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{1-methyl-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-dimethylphenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide ;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;
2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;
2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dichlorophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-m ethylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide ;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
2-[4-(4-Cyanophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
diastereoisomers or enantiomers thereof and pharmaceutically acceptable salts (e.g. hydrochloride) thereof .

8 A compound selected from
[N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(*S*)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide (enantiomer 1);
N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(1-methyl-4-phenyl-piperidin-4-yl)-N-methyl-acetamide (enantiomer 1);
N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide (enantiomer 1);
and pharmaceutically acceptable salts thereof (e.g. hydrochloride).

9. A process (A) for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein $R_6$ is a nitrogen protecting group or (CH2)r$R_7$ , with amine (III)




(II)




(III)

wherein $R_2$ is hydrogen, $C_{1-4}$ alkyl or a nitrogen protecting group, followed where necessary by removal of any nitrogen protecting group; or a process B for the preparation of a compound of formula(I) wherein $R_2$ is C $_{1-4}$ alkyl which comprises the reaction of a compound of formula(Ia), with (C $_{1-4}$ alkyl)L wherein L is a suitable leaving group selected from iodine, bromine.




(Ia)

10. A compound as claimed in any claims 1 to 8 for use in therapy.

11. The use of a compound as claimed in any claims 1 to 8 in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins (including substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

12. The use of a compound as claimed in any claims 1 to 8 in the treatment of conditions mediated by tachykinins (including substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

13. A pharmaceutical composition comprising a compound as claimed in any claims 1 to 8 in admixture with one or more pharmaceutically acceptable carriers or excipients.

14. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other

neurokinins and/or by selective inhibition of the serotonin reuptake transporter protein comprising administration of an effective amount of a compound of formula (I) as claimed in any claims 1 to 8.